New Drug extends breast cancer patients Age

A new drug for breast cancer with Kadcyla generic name has been approved by the U.S. Food and Drug Administration ( FDA). The drug is claimed to increase the life expectancy of patients with advanced up to six more months stage.
Kadcyla target tumor cells without damaging healthy cells . This medicine can help improve the life expectancy is better. A patient , Lisa Canales (50) , who had been battling breast cancer for 15 years feel an improvement since obtaining drugs Kadcyla .

" A good way to explain the mechanism of this drug is the parable : if we turn off the lights on the ceiling, we had to turn off all lights However, with this drug, we can go to that we turn off the lights without off each other . " said dr . Marc Citron , director of cancer services at ProHealth Care Associates.

Lemon said , these drugs can offer a better advantage than before treatment . This is because these drugs can delay the progression of cancer cells for several months. Kadcyla provide better treatment with fewer side effects.
" This treatment is remarkable, because it can give me the opportunity to do the things I do. I do not have time to feel bad , because I spent 16 years of my time with cancer" said Canales .

The drug is used primarily for cancer stage or metastatic Human Epidermal growth factor Receptor -2 ( HER- 2) positive gene dissemination. Positive HER- 2 is a protein produced by a gene that could potentially cause cancer. Kadcyla combined with the use of the drug Herceptin ( trastuzumab) and taxane chemotherapy .

Doctors hope to the more widespread use of Kadcyla to fight breast cancer in the future.

" These drugs are being considered for use on the stage of early breast cancer in patients before surgery, and the patient after surgery. Generally , if an effective drug for cancer at a advanced stage , it will be more effective in the previous step , "said lemon.

0 Response to "New Drug extends breast cancer patients Age"

Post a Comment